Xenon Pharmaceuticals Inc. (XENE)
NEUTRALFundamental
29
मूल्य
$60.63
मार्केट कैप
$5.88B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$8M
31/12/2025 को समाप्त वित्त वर्ष
शुद्ध आय
$-346M
31/12/2025 को समाप्त वित्त वर्ष
Free Cash Flow
$-280M
कुल इक्विटी
$582M
कुल देनदारियाँ
$51M
Current Ratio
21.02
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$81.30
वर्तमान मूल्य
$60.63
Margin of Safety
+25.4%
Fair Value सीमा
$77.23 - $85.36
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-59.5%
P/B Ratio
4.72
P/FCF
-
Gross Margin
-
ROIC
-27.9%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-27.9%
WACC
8.0%
ROIC − WACC
-35.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (6)
- Price CAGR 22.95%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 96% Buy
- Share Dilution 1.9%
फेल (11)
- EPS shows upward trend
- ROIC -27.9%
- P/B Ratio 4.72
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -44.0%
- Revenue Growth 5Y -25.3%
- Earnings Surprise avg 0.5%
- Piotroski F-Score 2/9
अनुपलब्ध (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर संख्या स्थिर है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director | 49 |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer | 54 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 57 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 54 |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer | 61 |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer | 53 |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources | 65 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 64 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 64 |
| Ms. Colleen Alabiso | Senior Vice President of Corporate Affairs | - |
Audit जोखिम
5
बोर्ड जोखिम
1
मुआवजा जोखिम
8
शेयरधारक अधिकार जोखिम
3
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for XENE, sourced from Markets Gazette.
- 3/9/2026POSITIVEXenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals Inc. experienced a significant share price surge following the release of positive Phase 3 clinical trial data for its drug azetukalner. The pivotal study demonstrated a substantial reduction in monthly seizures for patients treated with the drug. This success paves the way for Xenon to file for FDA approval in 2026. The strong clinical results and clear regulatory path are highly encouraging for investors, potentially positioning azetukalner as a significant new treatment option and driving future revenue growth for the company.
via Markets Gazette